Company Description
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson’s disease and other synucleinopathies.
The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer’s disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aβ-Tau Vaccine, which is in preclinical trial for treating Alzheimer’s disease.
In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aβ antibody which is in phase 1 clinical trial to treat Alzheimer’s disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer’s disease.
It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target α-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43.
Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
| Country | Ireland |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 163 |
| CEO | Gene Kinney |
Contact Details
Address: 77 Sir John Rogerson’s Quay, Block C Dublin, D02 VK60 Ireland | |
| Phone | 353 1 236 2500 |
| Website | prothena.com |
Stock Details
| Ticker Symbol | PRTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001559053 |
| CUSIP Number | G72800108 |
| ISIN Number | IE00B91XRN20 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gene G. Kinney Ph.D. | President, Chief Executive Officer and Director |
| Tran B. Nguyen M.B.A. | Chief Financial Officer and Chief Strategy Officer |
| Brandon S. Smith | Chief Operating Officer |
| Dr. Wagner M. Zago Ph.D. | Chief Scientific Officer |
| Karin L. Walker CPA | Chief Accounting Officer and Controller |
| Mark C. Johnson C.F.A. | Vice President of Investor Relations |
| Michael J. Malecek | Chief Legal Officer and Company Secretary |
| Dr. Chad H. Swanson Ph.D. | Chief Development Officer |
| Phillip Dolan | Senior Director and Head of Exploratory Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | EFFECT | Notice of Effectiveness |
| Feb 27, 2026 | 8-K | Current Report |
| Feb 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Feb 27, 2026 | 10-K | Annual Report |
| Feb 27, 2026 | POSASR | Filing |
| Feb 19, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G | Filing |
| Dec 12, 2025 | 8-K | Current Report |
| Nov 19, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |